Evidence map›Paper›PMID 36536424›Full record

Observational studyBMC research notes2022

Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease.

Niki Katsiki, Nikolaos Tentolouris, Georgios Marakomichelakis, Dimitrios Richter, Athanasios Giannoukas, Panagiota Koufaki, Nikolaos Papanas, CI-WIN Investigators

Open access · goldAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC research notes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Niki KatsikiDepartment of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.
Nikolaos TentolourisFirst Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Georgios MarakomichelakisFourth Department of Internal Medicine and Angiology Unit, Evangelismos General Hospital, Athens, Greece.
Dimitrios RichterCardiac Department, Euroclinic Hospital, Athens, Greece.
Athanasios GiannoukasDepartment of Vascular Surgery, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Panagiota KoufakiWINMEDICA Hellas, Athens, Greece.
Nikolaos PapanasDiabetic Foot Clinic, Diabetes Centre, Second Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. papanasnikos@yahoo.gr.ORCID http://orcid.org/0000-0002-7320-785X
CI-WIN Investigators
Evangelismos Hospital · GRAthens Euroclinic · GRDemocritus University of Thrace · GREuromedica · GRInternational Hellenic University · GRNational and Kapodistrian University of Athens · GRUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveto assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study. We included 1015 PAD patients presenting with IC (71.3% men, 93.5% white, mean age 69.2 ± 8.7 years). Patients were followed up for 6 months by their physicians.

resultsCilostazol significantly increased pain-free walking distance by a median of 285 and 387 m at 3 and 6 months, respectively (p < 0.01 for all comparisons). This effect was significant for patients 50-74 years (but not for those aged ≥ 75 years) and independent of smoking status, changes in physical activity, comorbidities and concomitant medication for PAD (i.e., acetylsalicylic acid and clopidogrel). Furthermore, significant reductions were observed in systolic (from 139 ± 16 to 133 ± 14 mmHg; p < 0.001) and diastolic blood pressure (from 84 ± 9 mmHg to 80 ± 10 mmHg; p < 0.001). Smoking cessation and increased physical activity were reported by the majority of participants. In conclusion, cilostazol was shown to safely decrease pain symptoms and improve pain-free walking in PAD patients with IC in a real world setting. Benefits also occurred in terms of BP and lifestyle changes.

Indexed as

Intermittent ClaudicationPeripheral Arterial DiseaseAgedCilostazolFemaleHumansMaleMiddle AgedPainProspective StudiesTetrazolesWalkingCilostazolTetrazolesCilostazolIntermittent claudicationPain-free walking distancePeripheral arterial disease

Identifiers

PMID36536424
PMCPMC9764459
OpenAlexW4312095254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.